Your browser is no longer supported. Please, upgrade your browser.
AXLA Axcella Health Inc. daily Stock Chart
Axcella Health Inc.
Index- P/E- EPS (ttm)-6.04 Insider Own3.50% Shs Outstand22.55M Perf Week-3.33%
Market Cap117.94M Forward P/E- EPS next Y-2.24 Insider Trans- Shs Float21.74M Perf Month-18.28%
Income- PEG- EPS next Q-0.71 Inst Own62.30% Short Float0.18% Perf Quarter-35.51%
Sales- P/S- EPS this Y-16.60% Inst Trans0.06% Short Ratio3.89 Perf Half Y-
Book/sh5.91 P/B0.88 EPS next Y32.50% ROA- Target Price17.00 Perf Year-
Cash/sh5.23 P/C1.00 EPS next 5Y- ROE- 52W Range4.79 - 15.99 Perf YTD-62.10%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-67.29% Beta-
Dividend %- Quick Ratio17.40 Sales past 5Y- Gross Margin- 52W Low9.19% ATR0.44
Employees55 Current Ratio17.40 Sales Q/Q- Oper. Margin- RSI (14)37.80 Volatility6.73% 8.47%
OptionableNo Debt/Eq0.27 EPS Q/Q- Profit Margin- Rel Volume0.48 Prev Close5.23
ShortableYes LT Debt/Eq0.27 EarningsNov 11 AMC Payout- Avg Volume10.28K Price5.23
Recom1.70 SMA20-5.37% SMA50-20.90% SMA200-41.14% Volume0 Change0.00%
Jun-03-19Initiated SVB Leerink Outperform $21
Jun-03-19Initiated JP Morgan Overweight $20
Jun-03-19Initiated Goldman Buy $25
Oct-11-19 05:49PM  Bay Area biotech unicorn suffers 5th worst Wall Street debut of year American City Business Journals
Oct-07-19 08:30AM  Axcella Provides Progress Updates for Liver Program Candidates AXA1125 and AXA1957 Business Wire
Oct-01-19 04:11PM  Axcella Announces Presentations at the American Association for the Study of Liver Disease (AASLD) The Liver Meeting Business Wire -6.01%
Sep-03-19 05:45AM  The 4 Worst IPOs So Far This Year
Aug-23-19 04:27PM  Axcella Health Inc. Announces Appointment of Catherine A. Sohn, Pharm. D. to its Board of Directors Business Wire
Aug-12-19 05:06PM  Axcella Health Reports Second Quarter 2019 Financial Results and Provides Company Update Business Wire
Aug-08-19 10:48AM  What Type Of Shareholder Owns Axcella Health Inc.'s (NASDAQ:AXLA)? Simply Wall St.
Aug-07-19 05:54PM  Axcella to Present at the Wedbush PacGrow Healthcare Conference Business Wire
Jul-31-19 08:00AM  Axcella Announces Publication of Data Describing Attenuation of Muscle Atrophy with AXA2678 in Short-Term Muscle Disuse Study Business Wire
Jun-20-19 05:10PM  Axcella Health Reports First Quarter 2019 Financial Results and Provides Company Update GlobeNewswire
May-13-19 05:30PM  Axcella Health Announces Closing of Initial Public Offering GlobeNewswire
May-08-19 08:40PM  Axcella Health Announces Pricing of Initial Public Offering GlobeNewswire
07:11AM  Uber in drivers seat as IPO market gears up for busiest week since 2015 MarketWatch
May-06-19 06:08PM  The Axcella Health IPO: What You Need To Know Benzinga
May-04-19 05:25PM  IPO Outlook For The Week: Uber (And 11 Others) Benzinga
Axcella Health Inc., a biotechnology company, researches and develops novel multifactorial interventions to support health and address dysregulated metabolism in the United States. The company develops its products based on its AXA Development Platform. It offers AXA1665 for use in treating hepatic encephalopathy; AXA1125 and AXA1957 to treat non-alcoholic fatty liver disease; AXA2678 for use in treating immobilization-induced acute muscle atrophy; and AXA4010 to target multiple biological pathways. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was founded in 2008 and is based in Cambridge, Massachusetts.